Conference Call with Ajanta Pharma Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Ajanta Pharma announced Q1FY26 results Revenue from operations at Rs 1,303 crore. against Rs 1,145 crore; up 14%. EBITDA at Rs 351 crore. against Rs 330 crore, up 6%; EBITDA at 27%. Profit after tax at Rs 255 crore. against Rs 246 crore; up 4%; PAT at 20%. The mark-to-market forex loss stood at Rs 25 crore. Excluding this impact, EBITDA stood at Rs 376 crore, reflecting a 14% growth, with an EBITDA margin of 29%. PAT grew by 12%, with a PAT margin of 21%. Cashflow from operations (CFO) was Rs 282 crore, EBITDA to CFO conversion of 80%. Free cashflow (FCF) was Rs 209 crore, FCF to PAT conversion of 82%. ROCE stood at a healthy level of 33% and RONW at 26%. Result PDF
Conference Call with Ajanta Pharma Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Ajanta Pharma announced Q4FY25 & FY25 results Q4FY25 FInancial Highlights: Revenue from operations at Rs 1,170 crore against Rs 1,054 crore; up 11%. EBITDA at Rs 297 crore against Rs 278 crore; up 7%; EBITDA at 25%. Profit after tax at Rs 225 crore against Rs 203 crore; up 11%; PAT at 19%. FY25 FInancial Highlights: Revenue from operations at Rs 4,648 crore against Rs 4,209 crore; up 10%. EBITDA at Rs 1,260 crore against Rs 1,172 crore; up 7%; EBITDA at 27%. Profit after tax at Rs 920 crore against Rs 816 crore; up 13%; PAT at 20%. Cashflow from operations (CFO) was Rs 1,157 crore, EBITDA to CFO conversion of 92%. Free cashflow (FCF) was Rs 694 crore, FCF to PAT conversion of 75%. ROCE stood at a healthy level of 32% and RONW at 25%. Result PDF